| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 03/30/2006 | US20060067928 Contacting a linear polysaccharide with a disaccharide repeat unit of a uronic acid [ alpha -L-iduronic acid (I) or beta -D-glucuronic acid] linked 1, 4 to alpha -D-hexosamine with a modified heparinase III in vitro |
| 03/30/2006 | US20060067920 Chimeric immunoreceptor useful in treating human cancers |
| 03/30/2006 | US20060067919 Colon cancer metastasis inhibitor |
| 03/30/2006 | US20060067890 Telomelysin/GFP-expressing recombinant virus |
| 03/30/2006 | CA2619256A1 Polynucleotides and polypeptides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover |
| 03/30/2006 | CA2583413A1 Delivery of polynucleotides |
| 03/30/2006 | CA2579677A1 Compositions and methods for protein production |
| 03/30/2006 | CA2579374A1 Aptamers to von willebrand factor and their use as thrombotic disease therapeutics |
| 03/30/2006 | CA2577519A1 Multiple rna polymerase iii promoter expression constructs |
| 03/30/2006 | CA2571159A1 Aav mediated gene delivery to cochlear cells |
| 03/30/2006 | CA2563304A1 Method of modulating vascularization |
| 03/29/2006 | EP1640452A1 OLIGO DOUBLE-STRANDED RNA INHIBITING THE EXPRESSION OF Bcl-2 AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| 03/29/2006 | EP1640381A2 Neurotrophic growth factor |
| 03/29/2006 | EP1639112A2 Novel beta-actin and rps21 promoters and uses thereof |
| 03/29/2006 | EP1639029A2 Biodegradable poly(beta-amino esters) and uses thereof |
| 03/29/2006 | EP1639006A1 Use of a vegf receptor gene or gene product |
| 03/29/2006 | EP1639001A1 Method for transplanting lymphohematopoietic cells into mammal |
| 03/29/2006 | EP1638999A2 Compositions and methods for increasing bone mineralization |
| 03/29/2006 | EP1638987A2 Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for using the same |
| 03/29/2006 | EP1638919A1 Sphingolipids polyalkylamines conjugates |
| 03/29/2006 | EP1638611A1 Sphingolipids polyalkylamine conjugates for use in transfection |
| 03/29/2006 | EP1638610A1 Sphingoid polyalkylamine conjugates for vaccination |
| 03/29/2006 | EP1638593A1 Proton-sensing g-protein coupled receptors and dna sequences thereof |
| 03/29/2006 | EP1638587A2 Contraceptive methods and compositions related to proteasomal interference |
| 03/29/2006 | EP1434855A4 Adipose-derived stem cells and lattices |
| 03/29/2006 | EP1411971B1 Use of long pentraxin ptx3 for treating female infertility |
| 03/29/2006 | EP1346039B1 Human cervical cancer 2 protooncogene and protein encoded therein |
| 03/29/2006 | EP1289552B1 Methods for treating hemostatic disorders by soluble p-selectin |
| 03/29/2006 | EP1230267B1 Membrane translocating peptide drug delivery system |
| 03/29/2006 | EP1226279B1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 03/29/2006 | EP1222266B1 Pca3 messenger rna in benign and malignant prostate tissues |
| 03/29/2006 | EP1181376B1 Gene construct for prodrug activation encoding a heterologous, glycosylphophatidylinositol-modified carboxypeptidase g2 and a cell surface targeting signal peptide |
| 03/29/2006 | EP1156789B1 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 03/29/2006 | EP1086224B1 B2 microglobulin fusion proteins and high affinity variants |
| 03/29/2006 | EP1012331B1 Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| 03/29/2006 | EP0990031B1 Tumor necrosis factor receptor 5 |
| 03/29/2006 | EP0954598B1 Screening assay for compounds stimulating somatostatin and insulin production |
| 03/29/2006 | EP0944722B1 Pituitary-tumor-transforming-genes, and related products |
| 03/29/2006 | EP0751709B2 Use of bcl-2 for the manufacture of medicaments for the therapeutic treatment and prevention of diseases |
| 03/29/2006 | CN1753993A Detection of small nucleic acids |
| 03/29/2006 | CN1753909A Peptides and pharmaceutical compositions comprising said peptides and medical composition for treating cancer |
| 03/29/2006 | CN1753904A Bmp-2 estrogen responsive element and methods of using the same |
| 03/29/2006 | CN1753689A The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy |
| 03/29/2006 | CN1753686A Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| 03/29/2006 | CN1753618A Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| 03/29/2006 | CN1247788C Lentivirus-Based gene transfer vectors. |
| 03/29/2006 | CN1247780C Mammalian sytokine-like polypeptide-10 |
| 03/29/2006 | CN1247779C Gene target sequence box |
| 03/29/2006 | CN1247775C Attenuated cattle viral diarrhoea virus |
| 03/29/2006 | CN1247608C Gene therapeutic drug hdm2-siRNA for breast cancer |
| 03/28/2006 | US7019125 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 03/28/2006 | US7019108 Especially the amino acid sequence Ile-Phe-Ala-Gly-Asp-Lys-Phe-Trp-Arg, preferably flanked by cysteine residues at the amino and carboxy termini. |
| 03/28/2006 | US7018835 Cap independent translation enhancer linked with genetic sequence; expressed immunogen in eukaryote cell; antisense agents, vaccines for anthrax, tuberculosis, genetic vaccines; semliki forest virus immunogen, bacterial vaccine vector |
| 03/28/2006 | US7018834 Vaccines; gene therapy; genetic engineering |
| 03/28/2006 | US7018833 Monitoring gene expresion pattern from preferential promoter; obtain expression vector, incubate with cells, monitor expression vector, evaluate gene expression pattern |
| 03/28/2006 | US7018832 Transport proteins for use in the treatment and diagnosis of stroke, pain, neuropathic pain and traumatic brain injury |
| 03/28/2006 | US7018810 Chordin-like molecules and uses thereof |
| 03/28/2006 | US7018645 biodegradable and water soluble polyesterether block polymers used for drug delivery |
| 03/28/2006 | US7018631 Compositions and methods for sensitizing and inhibiting growth of human tumor cells |
| 03/28/2006 | US7018628 Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates |
| 03/28/2006 | US7018609 For drug delivery |
| 03/28/2006 | CA2291892C Angiostatin fragments and method of use |
| 03/28/2006 | CA2096723C Methods and compositions for the suppression of neu mediated transformation |
| 03/23/2006 | WO2006032041A2 Compositions and methods for inhibiting expression of anti-apoptotic genes |
| 03/23/2006 | WO2006031977A2 Inhibition of pancreatic cancer cell growth |
| 03/23/2006 | WO2006031901A2 SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF |
| 03/23/2006 | WO2006031703A1 Cytokine-expressing cellular vaccines for treatment of prostate cancer |
| 03/23/2006 | WO2006031471A2 Liposomal vectors |
| 03/23/2006 | WO2006031467A2 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
| 03/23/2006 | WO2006031313A2 Methods and compositions for cell activation |
| 03/23/2006 | WO2006031267A2 Rna interference suppression of neurodegenerative diseases and methods of use thereof |
| 03/23/2006 | WO2006031213A1 Single -pass image warping system and mehtod with anisotropic filtering |
| 03/23/2006 | WO2006030693A1 Agents for overcoming hair troubles and method of screening the same |
| 03/23/2006 | WO2006029831A1 Conditional gene vectors regulated in cis |
| 03/23/2006 | WO2005112542A3 Cartilage and bone repair composition |
| 03/23/2006 | WO2005112541A3 Adenovirus/alphavirus hybrid vector for the effective administration and expression of therapeutic genes in tumour cells |
| 03/23/2006 | WO2005110491A8 Inducible dimerization of growth factor receptors for treating cancer |
| 03/23/2006 | WO2005097981A3 Novel herpes simplex viruses |
| 03/23/2006 | WO2005077337A3 Dispersions prepared by use of self-stabilizing agents |
| 03/23/2006 | WO2005059111A3 DELIVERY OF DNA OR RNA VIA GAP JUNCTIONS FROM HOST CELLS TO TARGET CELLS AND A CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR SiRNA |
| 03/23/2006 | WO2005046585A3 Vps35-based assays and methods for treating alzheimer’s disease |
| 03/23/2006 | WO2005040340A3 Rnai-based modification of heterochromatin |
| 03/23/2006 | WO2005013886A3 Methods for treating and preventing apoptosis-related diseases using rna interfering agents |
| 03/23/2006 | WO2005013802A3 Trefoil factor 3 (tff3) as a target for anti-cancer therapy |
| 03/23/2006 | WO2005007623A8 Inhibition of syk kinase expression |
| 03/23/2006 | WO2004108939A3 BAV packaging regions and E1 transcriptional control regions |
| 03/23/2006 | WO2004101799A3 Broadening adenovirus tropism |
| 03/23/2006 | WO2004096117A3 Drug delivery systems comprising transferrin-nucleic acid conjugates |
| 03/23/2006 | US20060063922 Epidermal differentiation factor |
| 03/23/2006 | US20060063734 4,7-dichlorofluorescein dyes as molecular probes |
| 03/23/2006 | US20060063733 Methods of reducing an immune response |
| 03/23/2006 | US20060063732 Compositions and methods for gene therapy |
| 03/23/2006 | US20060063731 In vivo inhibition of hepatitis B virus |
| 03/23/2006 | US20060063730 Enhanced antisense oligonucleotides |
| 03/23/2006 | US20060063729 Ocular gene therapy |
| 03/23/2006 | US20060063728 Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease |
| 03/23/2006 | US20060063727 Tr4/tr2 response elements |
| 03/23/2006 | US20060063697 Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses |
| 03/23/2006 | US20060063258 Retinoic acid receptor beta-2, its agonists, and gene therapy vectors for the treatment of neurological disorders |
| 03/23/2006 | US20060063235 DNA encoding the human serine protease C-E |